NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Goldman to Buy. $15 price target. Free cash flow is increasing and the company should soon announce a dividend increase.
initiated at Barclays with an Overweight rating as the company is on track for long term growth. $17 price target. 2009 and 2010 EPS estimates set at $0.85 and $1.06, respectively.
upgraded at Citigroup from Sell to Hold. $32 price target. Power prices have edged higher and the company recent posted strong earnings.
Pharmaceutical Product Dev.
( PPDI) downgraded at Wells from Outperform to Market Perform. Booking and core earnings power continue to decline.
upgraded at FBR to Outperform. $23 price target. Valuation is attractive, but the RCI division should continue to grow.
STOCK COMMENTS / EPS CHANGES
estimates, target increased at Goldman. Shares now seen reaching $19. Estimates also boosted, as the company is finding ways to grow, despite rising competition. Sell rating.
price target, estimates raised at Barclays. Price target lifted to $59 from $56. 2009 EPS estimate inflated to $3.90 from $3.75, 2010 raised by 5 cents to $6.05.
price target, numbers boosted at Barclays. Price target lifted to $93 from $85 on transportation volumes. 2010 EPS estimates raised by a penny to $3.44, 2011 surged to $4.50 from $4.05. Maintain Overweight rating.
price target, estimates cut at Barclays. FSLR price target down to $150 from $160 following weak 3Q results. 2009 and 2010 EPS estimates cut to $7.36 from $8.16 and to $6.57 from $7.28, respectively. Reiterate Equal Weight rating.
target cut at Citigroup. Shares now seen reaching $140. Margins will remain down as the company will be forced to compete on price. Hold rating.
numbers boosted at FBR. Shares now seen reaching $68. Estimates also raised, to reflect a better subsea outlook and expectations for higher margins. Outperform rating.
( GSIC) numbers raised at Goldman. GSIC estimates were increased through 2011. Company is seeing higher same-store sales. Neutral rating and new $21 price target.
numbers lowered at Goldman. Shares now seen reaching $17. Estimates also reduced, to reflect higher raw materials costs and interest expense. Neutral rating.
estimates boosted at Goldman through 2011. Company boosted it sales forecast, which will lead to higher margins. Buy rating and $42 price target.
estimates trimmed at Goldman through 2011. See a slower revenue build, given the guidance for Spring orders, though cost-cutting initiatives continue to work. Neutral rating and $20.50 price target.
estimates lowered at Goldman through 2011. Company is seeing a higher tax rate and share count. Buy rating and $48 price target.
estimates mixed at Barclays. Lowered LLY 2009 EPS estimates to $4.48 from $4.50, 2010 raised to $4.74 from $4.54. Maintain Equal Weight rating and $39 price target.
estimates raised at Goldman through 2011. Enterprise sales are recovering. Buy rating and $6.50 price target.
numbers boosted at Goldman. Shares now seen reaching $27. Estimates also raised, to reflect higher realized margins. Neutral rating.
NY Community Banc
( NYB) numbers boosted at FBR. Shares now seen reaching $11. Estimates also raised, to reflect capital actions. Market Perform rating.
numbers increased at Goldman. Estimates were raised through 2011. Company boosted its sales outlook and is seeing more favorable input costs. Neutral rating and new $66 price target.
PSS World Medical
( PSSI) estimates raised at Goldman through 2010. Company benefited from H1N1 sales and higher margins in the Physician's segment. Neutral rating and $23 price target.
estimates raised at Goldman through 2011. Company is cutting costs, but a near-term sales recovery is not likely. Sell rating and $3 price target.
cut from Conviction Buy List at Goldman. Stock has underperformed and concerns are rising about near-term earnings power. $8 price target.
numbers boosted at Goldman. Shares now seen reaching $22. Estimates also raised, to reflect lower a share count and tax rate. Sell rating.
price target cut, estimates changed at Barclays. Price target dropped to $39 from $43 on valuation. 2009 EPS raised to $1.93 from $1.87, 2010 cut by a penny to $2.15. Maintain Equal Weight rating.
estimates raised at FBR through 2011. Company sold its unprofitable mortgage and real estate loan portfolio. Outperform rating and $15 price target.
estimates, target cut at FBR. Shares now seen reaching $48. Estimates also lowered, to reflect continued late-cycle headwinds. Market Perform rating.
estimates, target boosted at Goldman. Shares of SYMC now seen reaching $20. Estimates also raised, to reflect better consumer growth and higher realized margins. Neutral rating.
Time Warner Cable
price target up, estimate down at Barclays. Price target raised to $43 from $35. 2009 EPS estimate maintained at $3.05, 2010 tweaked to $3.50 from $3.54. Reiterate Equal Weight rating.
price target, estimate raised at Barclays. Price target to $65 from $60. Maintain 2009 EPS estimate at $2.20, 2010 lifted to $3.05 from $2.95. Reiterate Overweight rating.
price target, estimates higher at Barclays. WLP price target increased to $62 from $57. 2009 and 2010 EPS estimates raised to $5.87 from $5.65 and to $6.20 from $6.00, respectively. Maintain Overweight rating.
price target, estimates boosted at Barclays. XL price target to $18 from $13 after strong 3Q results. 2009 and 2010 EPS estimates increased to $2.70 from $2.30 and to $2.25 from $1.90, respectively. Maintain Equal Weight rating.
This article was written by a staff member of TheStreet.com.